ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors
Objectives: Neurotrophic tropomyosin receptor kinase (NTRK) fusions might be an off-target resistance mechanism to ALK Tyrosine Kinase Inhibitors (TKIs) in the same way as it has been suggested with activating epidermal growth factor receptor (EGFR) TKIs. Materials and methods: DNA and RNA next-gene...
Guardado en:
Autores principales: | Elena Corral de la Fuente, Amparo Benito Berlinches, Ana Gomez Rueda, María Eugenia Olmedo García, Yolanda Lage Alfranca, Margaret Lario, Almudena Santón Roldán, Pilar Garrido |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5880d69d21dd4dc1b807fb5ddf5f7f20 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Huan Zhang, et al.
Publicado: (2021) -
Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
por: Liang L, et al.
Publicado: (2021) -
Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng L, et al.
Publicado: (2018) -
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
por: Schrock AB, et al.
Publicado: (2020) -
Manejo clínico y terapéutico de un tumor fibroso pleural con translocación de ALK
por: Patricia Cruz-Castellanos, et al.
Publicado: (2021)